Related Experiment Video

Updated: Mar 18, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

miRNAs: mediators of ErbB family targeted therapy resistance

Bárbara Filipa Adem1,2, Nuno Ricardo Alves Bastos1,2, Francisca Dias1,3,4

  • 1Molecular Oncology & Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr António Bernardino de Almeida, 4200-072 Porto, Portugal.

Pharmacogenomics
|July 1, 2016
PubMed

Insights

Targeted therapies for ErbB/HER family receptors in cancer show promise but face acquired resistance. MicroRNAs (miRNAs) are emerging as key mediators of this resistance, offering potential for new exosome-based miRNA therapeutics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The ErbB/HER tyrosine kinase receptor family is crucial for cellular processes.
  • Aberrant ErbB signaling, through mutations or overexpression, is common in various cancers.
  • Targeted therapies against ErbB family receptors represent a move towards personalized cancer medicine.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) in acquired resistance to ErbB-targeted therapies.
  • To explore the potential of miRNA-based therapeutics for overcoming cancer treatment resistance.

Main Methods:

  • Review of current literature on ErbB signaling, targeted therapies, and miRNA involvement in cancer.
  • Analysis of studies identifying miRNAs as mediators of acquired resistance to ErbB inhibitors.
  • Exploration of exosome-mediated drug delivery systems for miRNA therapeutics.

Main Results:

  • Acquired resistance remains a significant challenge in ErbB-targeted cancer therapy.
  • MicroRNAs have been identified as critical mediators of acquired resistance to ErbB family targeted therapies.
  • Exosomes show potential as effective delivery vehicles for miRNA-based cancer therapeutics.

Conclusions:

  • Understanding miRNA-mediated resistance mechanisms is vital for improving cancer treatment outcomes.
  • miRNA-based therapeutics, delivered via exosomes, hold promise for revolutionizing cancer treatment strategies.
  • Further research into exosome-based miRNA delivery could lead to more effective and personalized cancer therapies.
Keywords:
ErbB familyacquired resistanceexosomesmiRNAstargeted therapies

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.8K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K